DK3544634T3 - MET-antistof-lægemiddelkonjugater - Google Patents

MET-antistof-lægemiddelkonjugater Download PDF

Info

Publication number
DK3544634T3
DK3544634T3 DK17817374.6T DK17817374T DK3544634T3 DK 3544634 T3 DK3544634 T3 DK 3544634T3 DK 17817374 T DK17817374 T DK 17817374T DK 3544634 T3 DK3544634 T3 DK 3544634T3
Authority
DK
Denmark
Prior art keywords
antibody
met
drug conjugates
conjugates
drug
Prior art date
Application number
DK17817374.6T
Other languages
English (en)
Inventor
Yiqing Feng
Philip Arthur Hipskind
Renhua Li
Ling Liu
Takako Wilson
Aaron David Wrobleski
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK3544634T3 publication Critical patent/DK3544634T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
DK17817374.6T 2016-11-23 2017-11-17 MET-antistof-lægemiddelkonjugater DK3544634T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662425853P 2016-11-23 2016-11-23
PCT/US2017/062247 WO2018098035A1 (en) 2016-11-23 2017-11-17 Met antibody drug conjugates

Publications (1)

Publication Number Publication Date
DK3544634T3 true DK3544634T3 (da) 2021-06-07

Family

ID=60703003

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17817374.6T DK3544634T3 (da) 2016-11-23 2017-11-17 MET-antistof-lægemiddelkonjugater

Country Status (15)

Country Link
US (1) US11167039B2 (da)
EP (1) EP3544634B1 (da)
JP (1) JP6951441B2 (da)
CN (1) CN110022903B (da)
CY (1) CY1124266T1 (da)
DK (1) DK3544634T3 (da)
ES (1) ES2875365T3 (da)
HR (1) HRP20210922T1 (da)
HU (1) HUE054500T2 (da)
LT (1) LT3544634T (da)
PL (1) PL3544634T3 (da)
PT (1) PT3544634T (da)
RS (1) RS61967B1 (da)
SI (1) SI3544634T1 (da)
WO (1) WO2018098035A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
US11896682B2 (en) 2019-09-16 2024-02-13 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof
CN115297889A (zh) * 2020-09-01 2022-11-04 荣昌生物制药(烟台)股份有限公司 抗c-Met抗体药物偶联物及其应用
CN117529499A (zh) 2021-02-03 2024-02-06 神话治疗股份有限公司 抗met抗体和其用途
WO2022214517A1 (en) * 2021-04-08 2022-10-13 Byondis B.V. Anti-c-met antibodies and antibody-drug conjugates

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
AU2006269940C1 (en) * 2005-07-18 2013-11-07 Seagen Inc. Beta-glucuronide-linker drug conjugates
PA8849001A1 (es) * 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
RS59253B1 (sr) * 2011-05-08 2019-10-31 Legochem Biosciences Inc Konjugati aktivnog agensa proteina i postupak za njihovo dobijanje
US20180280531A1 (en) 2014-12-08 2018-10-04 Sorrento Therapeutics, Inc. C-met antibody drug conjugate
KR20230028574A (ko) * 2016-05-17 2023-02-28 애브비 바이오테라퓨틱스 인크. 항-cMet 항체 약물 컨쥬게이트 및 그들의 이용 방법

Also Published As

Publication number Publication date
CN110022903A (zh) 2019-07-16
JP6951441B2 (ja) 2021-10-20
JP2019536780A (ja) 2019-12-19
SI3544634T1 (sl) 2021-08-31
CN110022903B (zh) 2022-06-03
PL3544634T3 (pl) 2021-09-27
EP3544634A1 (en) 2019-10-02
EP3544634B1 (en) 2021-04-14
HRP20210922T1 (hr) 2021-09-03
WO2018098035A1 (en) 2018-05-31
US20200061204A1 (en) 2020-02-27
ES2875365T3 (es) 2021-11-10
LT3544634T (lt) 2021-06-10
US11167039B2 (en) 2021-11-09
RS61967B1 (sr) 2021-07-30
HUE054500T2 (hu) 2021-09-28
CY1124266T1 (el) 2022-07-22
PT3544634T (pt) 2021-06-02

Similar Documents

Publication Publication Date Title
DK3592393T3 (da) Frigørbare konjugater
DK3579883T3 (da) Pyrrolobenzodiazepin-antistofkonjugater
DK3268047T3 (da) Amatoxin/antistof-konjugater
DK3525830T3 (da) Pyrrolobenzodiazepin-konjugater
DK3405050T3 (da) Børnesikret snusbeholder
DK3423104T3 (da) Amanitin-konjugater
DK3119885T3 (da) Antistof-fynomer-konjugater
DK3137114T3 (da) Anti-PTK7-antistof-lægemiddelkonjugater
DK3148591T3 (da) Nanopartikel-lægemiddelkonjugater
DK3436823T3 (da) Antigen-array
DK3612537T3 (da) Pyrrolobenzodiazepinkonjugater
DK3445708T3 (da) Stigbøjle
DK3402792T3 (da) Quinolin-2-on-derivater
DK3335532T3 (da) Tandharve
DK3509963T3 (da) Pallecontainer
DK3544634T3 (da) MET-antistof-lægemiddelkonjugater
DK3528829T3 (da) Bacitracin-alginat-oligomer-konjugater
DK3575238T3 (da) Pallecontainer
DE112017006386A5 (de) Schraubarbeitszylinder
DE112017000734A5 (de) Glycolsensor
DK3471535T3 (da) Dyrelift
DK3452587T3 (da) Penicillin-g-acylaser
DK3452590T3 (da) Plademagnet
DK3295800T3 (da) Sandwichkiksindretning
DE112017006474A5 (de) Gargerätevorrichtung